stoxline Quote Chart Rank Option Currency Glossary
  
Humacyte, Inc. (HUMA)
7.2  -0.14 (-1.91%)    06-13 16:00
Open: 7.28
High: 7.51
Volume: 1,292,940
  
Pre. Close: 7.34
Low: 6.99
Market Cap: 857(M)
Technical analysis
2024-06-13 4:43:57 PM
Short term     
Mid term     
Targets 6-month :  11.64 1-year :  13.6
Resists First :  9.97 Second :  11.64
Pivot price 7.4
Supports First :  6.48 Second :  4.32
MAs MA(5) :  7.19 MA(20) :  7.27
MA(100) :  4.41 MA(250) :  3.51
MACD MACD :  0.5 Signal :  0.6
%K %D K(14,3) :  30.5 D(3) :  30.4
RSI RSI(14): 56.2
52-week High :  9.97 Low :  1.96
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ HUMA ] has closed above bottom band by 40.2%. Bollinger Bands are 17.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.53 - 7.57 7.57 - 7.61
Low: 6.87 - 6.92 6.92 - 6.97
Close: 7.12 - 7.2 7.2 - 7.27
Company Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Headline News

Thu, 13 Jun 2024
Humacyte, Inc. (NASDAQ:HUMA) Director Sells $1,982,081.40 in Stock - MarketBeat

Thu, 13 Jun 2024
Humacyte Stockholders Elect Directors and Ratify Auditor at Annual Meeting - TipRanks.com - TipRanks

Thu, 13 Jun 2024
Humacyte announces board reshuffle and auditor ratification By Investing.com - Investing.com

Thu, 13 Jun 2024
Humacyte director Dougan sells over $4.5 million in company stock By Investing.com - Investing.com

Thu, 13 Jun 2024
Humacyte CEO Laura Niklason sells over $4.5 million in company stock By Investing.com - Investing.com

Thu, 13 Jun 2024
Humacyte (NASDAQ:HUMA) Trading Down 4.4% - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 119 (M)
Shares Float 84 (M)
Held by Insiders 30.6 (%)
Held by Institutions 19.8 (%)
Shares Short 4,190 (K)
Shares Short P.Month 3,940 (K)
Stock Financials
EPS -1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.21
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36.7 %
Return on Equity (ttm) -195.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.79
Qtrly Earnings Growth 0 %
Operating Cash Flow -82 (M)
Levered Free Cash Flow -52 (M)
Stock Valuations
PE Ratio -7.2
PEG Ratio 0
Price to Book value 32.72
Price to Sales 0
Price to Cash Flow -10.46
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android